Adalimumab for maintenance of remission in Crohn's disease

Townsend, Cassandra M; Nguyen, Tran M; Cepek, Jeremy; Abbass, Mohamad; Parker, Claire E; MacDonald, John K; Khanna, Reena; Jairath, Vipul; Feagan, Brian G.

doi:10.1002/14651858.cd012877.pub2

Cited by 13 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the overall remission rate at 12 months was considerably high as compared to the rates reported by a recent review aiming to evaluate the maintenance of remission with ADA therapy in CD. 23 In our population, the incidence of serious AEs was extremely low in both groups of patients. However, a higher percentage of patients reported mild AEs.…”

Section: Discussionmentioning

confidence: 59%

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

Tapete

Bertani

Pieraccini

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Few data are currently available about SB5 in inflammatory bowel diseases (IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort of patients with IBD in stable remission switched from the adalimumab (ADA) originator and in a cohort of patients with IBD naïve to ADA. Methods We prospectively enrolled patients with IBD who started ADA treatment with SB5 (naïve cohort) and those who underwent a nonmedical switch from the ADA originator to SB5 (switching cohort). Clinical remission and safety were assessed at baseline and at 3, 6, and 12 months. In addition, in a small cohort of patients who were switched, we assessed the ADA serum trough levels and antidrug antibodies at baseline, 3, and 6 months. Results In the naïve cohort, the overall remission rate at 12 months was 60.42%, whereas in the switching cohort it was 89.02%. Fifty-three (36.3%) patients experienced an adverse event, and injection site pain was the most common; it was significantly more frequent in the switching cohort (P = 0.001). No differences were found in terms of ADA serum trough levels at baseline, 3, and 6 months after switching. No patient developed antidrug antibodies after the switch. Conclusions We found that SB5 seemed effective and safe in IBD, both in the naïve cohort and in the switching cohort. Further studies are needed to confirm these data in terms of mucosal healing.

show abstract

Section: Discussionmentioning

confidence: 59%

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

Tapete

Bertani

Pieraccini

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Correspondingly, investigations of migraine treatment targeting the cytokines should be explored in future research as well. Interestingly, headache has been reported as a common side effect of treatment with TNF-a and IL-6 inhibitor and monoclonal antibodies (97)(98)(99)(100).…”

Section: Future Perspectives and Directionsmentioning

confidence: 99%

The role of cytokines in migraine: A systematic review

et al. 2022

View full text Add to dashboard Cite

Background Cytokines are important endogenous substances that are involved in immune and inflammatory responses. Neurogenic inflammation has been proposed to play a role in migraine involving altered cytokine levels. Therefore, we aimed to provide a systematic review on the current knowledge on cytokine levels in migraine patients during and outside attacks. Methods Databases of PubMed and Embase were systematically searched for studies investigating cytokine levels in migraine patients during and outside attacks. Results Screening yielded identification of 45 articles investigating 18 cytokines in total. We found that the interictal level of the anti-inflammatory cytokine, interleukin 10, was decreased, while the level of transforming growth factor beta 1 was increased in migraine patients compared to controls. Levels of pro-inflammatory cytokines, tumor necrosis factor α and interleukin 6, were increased outside attacks compared to controls. Ictal levels of cytokines were unchanged or varying compared to the interictal state in migraine patients. Three studies reported dynamic cytokines levels during the course of an attack. Conclusion The findings of the current review underline a possible involvement of cytokines in the proposed inflammatory mechanisms of migraine. However, future studies are needed to expand our knowledge of the exact role of cytokines in the migraine pathophysiology with focus on cytokines TNF-α, IL-1ß, IL-6 and IL-10 while applying refined methodology.

show abstract

“…One tissue that does appear to be sensitive to proinflammatory mediators, such as TNFα, is the intestinal tract, and lymphatic dysfunction does appear to play a pathogenic role in mouse models of inflammatory bowel disease ( Czepielewski et al, 2021 ). Also, considerable human clinical data supports that therapeutic efficacy of antibody blockade of TNFα in Crohn’s disease ( Townsend et al, 2020 ; Cui et al, 2021 ). Perhaps lymphatic capillary regression plays a pathogenic role in this disease.…”

Section: Discussionmentioning

confidence: 96%

Proinflammatory mediators, TNFα, IFNγ, and thrombin, directly induce lymphatic capillary tube regression

Kemp

Penn

Koller

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

In this work, we sought to investigate the direct effects of proinflammatory mediators on lymphatic endothelial cell (LEC) capillaries and whether they might induce regression. Our laboratory has developed novel in-vitro, serum-free, lymphatic tubulogenesis assay models whereby human LEC tube networks readily form in either three-dimensional collagen or fibrin matrices. These systems were initially conceptualized in the hopes of better understanding the influence of proinflammatory mediators on LEC capillaries. In this work, we have screened and identified proinflammatory mediators that cause regression of LEC tube networks, the most potent of which is TNFα (tumor necrosis factor alpha), followed by IFNγ (interferon gamma) and thrombin. When these mediators were combined, even greater and more rapid lymphatic capillary regression occurred. Surprisingly, IL-1β (interleukin-1 beta), one of the most potent and pathologic cytokines known, had no regressive effect on these tube networks. Finally, we identified new pharmacological drug combinations capable of rescuing LEC capillaries from regression in response to the potent combination of TNFα, IFNγ, and thrombin. We speculate that protecting lymphatic capillaries from regression may be an important step toward mitigating a wide variety of acute and chronic disease states, as lymphatics are believed to clear both proinflammatory cells and mediators from inflamed and damaged tissue beds. Overall, these studies identify key proinflammatory mediators, including TNFα, IFNγ, and thrombin, that induce regression of LEC tube networks, as well as identify potential therapeutic agents to diminish LEC capillary regression responses.

show abstract

Adalimumab for maintenance of remission in Crohn's disease

Cited by 13 publications

References 58 publications

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

The role of cytokines in migraine: A systematic review

Proinflammatory mediators, TNFα, IFNγ, and thrombin, directly induce lymphatic capillary tube regression

Contact Info

Product

Resources

About